Moderna, Inc. Debt Securities, Available-for-sale, Noncurrent
Moderna, Inc. (MRNA) had Debt Securities, Available-for-sale, Noncurrent of $1.77 billion as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-07-31
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $1.77B.
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $2.25B.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $2.34B.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $2.14B.
| Period end | Debt Securities, Available-for-sale, Noncurrent | Debt Securities, Available-for-sale, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $1.77B 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $2.25B 10-Q · filed 2026-05-01 | |
| 2025-12-31 | $2.34B 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $2.14B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $2.37B 10-Q · filed 2025-08-01 | |
| 2025-03-31 | $2.42B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $2.49B 10-K · filed 2026-02-20 | |
| 2024-09-30 | $2.33B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.33B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $3.64B 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $4.68B 10-K · filed 2025-02-21 | |
| 2023-09-30 | $5.27B 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $6.11B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $7.44B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $8.32B 10-K · filed 2024-02-23 | |
| 2022-09-30 | $8.65B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $10.16B 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $9.17B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $6.84B 10-K · filed 2023-02-24 | |
| 2021-09-30 | $6.44B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $4.21B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $468.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $639.00M 10-K · filed 2022-02-25 | $638.85M 10-K · filed 2021-02-26 |
| 2020-09-30 | $691.97M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $354.92M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $502.48M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $159.99M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $279.86M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $365.03M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $437.66M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $172.99M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $145.85M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |